Editorial: Nuclear Medicine in the Context of Personalized Medicine

Frontiers in Medicine

article

Jacques Barbet¹  Myriam Bernaudin²  Pierre Payoux³  Francesco Cicone⁵  Marie-Hélène Gaugler⁷  Françoise Kraeber-Bodéré⁷ 

[1] GIP Arronax;Université de Normandie, ISTCT/CERVOxy Group;Service de Médecine Nucléaire, CHU de Toulouse;Toulouse NeuroImaging Center;Department of Experimental and Clinical Medicine, “Magna Graecia” University of Catanzaro;Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital;Université de Nantes

关键词: PET;    theranostics;    radionuclide therapy;    solid tumors;    hematological malignancies;   

DOI  :  10.3389/fmed.2020.00252

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Nuclear Medicine has been at the heart of theranostics even before the term was coined. It provides effective tools for precision medicine particularly with positron emission tomography (PET), and radioligand therapy. It allows the investigation of phenotypes and functions in all areas of medicine and provides innovative tools to kill cancer cells. This Research Topic for Frontiers in Medicine focuses on the role of Nuclear Medicine in the context of Personalized Medicine. Three reviews reported the growing interest of PET in onco-hematological diseases. Jamet et al. have demonstrated the interest of 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) PET in the management of patients with multiple myeloma (MM). [18F]FDG-PET is highly sensitive and specific for bone lesions detection at baseline. The presence of extra-medullary disease, the number of bone focal lesions and the maximum standardized uptake value [SUVmax] have independent pejorative prognostic value on progression-free survival and overall survival. For therapy response assessment, [18F]FDG-PET is considered as the reference imaging technique. [18F]FDG-PET and bone marrow flow cytometry are complementary for detection of minimal residual disease before maintenance therapy. New PET tracers such as [11C]methionine, choline or acetate,[68Ga]Gapentixafor, which targets CXCR4, and immuno-PET targeting CD138 and CD38, also show promising results.

【 授权许可】

CC BY